Cargando…
Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations
T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia (T-LBL/T ALL) is an aggressive hematological malignancy arising from malignant transformation of T-cell progenitors with poor prognosis in adult patients. Outcomes are particularly dismal in the relapsed/refractory setting, and therap...
Autores principales: | Wong, Jonathan, Wall, Meaghan, Corboy, Gregory Philip, Taubenheim, Nadine, Gregory, Gareth Peter, Opat, Stephen, Shortt, Jake |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476415/ https://www.ncbi.nlm.nih.gov/pubmed/32843425 http://dx.doi.org/10.1101/mcs.a004994 |
Ejemplares similares
-
Broad genomic workup including optical genome mapping uncovers a DDX3X: MLLT10 gene fusion in acute myeloid leukemia
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2022) -
Discovery of an MLLT1/3 YEATS Domain Chemical Probe
por: Moustakim, Moses, et al.
Publicado: (2018) -
Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
por: Gregory, Gareth P., et al.
Publicado: (2019) -
Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
por: Won, Jong Mun, et al.
Publicado: (2023) -
Mature B cell acute lymphoblastic leukaemia with KMT2A-MLLT3 transcripts in children: three case reports and literature reviews
por: Cui, Yinghui, et al.
Publicado: (2021)